Last reviewed · How we verify
Placebo matching Saxagliptin
This is a placebo control formulation matching Saxagliptin, a DPP-4 inhibitor that increases incretin hormone levels to stimulate insulin secretion in response to glucose.
This is a placebo control formulation matching Saxagliptin, a DPP-4 inhibitor that increases incretin hormone levels to stimulate insulin secretion in response to glucose. Used for Placebo control for type 2 diabetes mellitus trials.
At a glance
| Generic name | Placebo matching Saxagliptin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | DPP-4 inhibitor (dipeptidyl peptidase-4 inhibitor) |
| Target | DPP-4 (dipeptidyl peptidase-4) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By blocking DPP-4, saxagliptin increases circulating levels of these incretin hormones, which enhance glucose-dependent insulin secretion and reduce glucagon secretion, thereby lowering blood glucose levels in type 2 diabetes. As a placebo matching formulation, this product contains no active saxagliptin and is used as a control in clinical trials.
Approved indications
- Placebo control for type 2 diabetes mellitus trials
Common side effects
- Hypoglycemia
- Upper respiratory tract infection
- Urinary tract infection
- Headache
Key clinical trials
- Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old (PHASE3)
- Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus (PHASE4)
- Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin (PHASE3)
- Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (PHASE4)
- A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD (PHASE2, PHASE3)
- Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients (PHASE4)
- Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone (PHASE3)
- Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching Saxagliptin CI brief — competitive landscape report
- Placebo matching Saxagliptin updates RSS · CI watch RSS
- AstraZeneca portfolio CI